Investment Management Associates Inc. ADV Has $8.01 Million Stock Holdings in Solventum Co. (NYSE:SOLV)

Investment Management Associates Inc. ADV lessened its position in Solventum Co. (NYSE:SOLV) by 5.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 114,898 shares of the company’s stock after selling 6,719 shares during the period. Solventum comprises approximately 3.1% of Investment Management Associates Inc. ADV’s holdings, making the stock its 14th biggest holding. Investment Management Associates Inc. ADV owned about 0.07% of Solventum worth $8,011,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in SOLV. Deseret Mutual Benefit Administrators acquired a new position in Solventum during the 2nd quarter valued at about $25,000. Hollencrest Capital Management acquired a new stake in shares of Solventum in the 2nd quarter valued at approximately $25,000. Partnership Wealth Management LLC acquired a new stake in shares of Solventum in the 2nd quarter valued at approximately $26,000. Richard W. Paul & Associates LLC acquired a new stake in Solventum during the 2nd quarter valued at $26,000. Finally, Family Firm Inc. acquired a new stake in Solventum during the 2nd quarter valued at $26,000.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Wolfe Research initiated coverage on Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating on the stock. Stifel Nicolaus assumed coverage on Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Piper Sandler lifted their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday. The Goldman Sachs Group lifted their price target on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research note on Monday, August 12th. Finally, BTIG Research assumed coverage on Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $68.00.

Solventum Stock Performance

Shares of NYSE SOLV opened at $71.53 on Tuesday. The business’s fifty day moving average price is $70.08 and its 200-day moving average price is $62.00. The company has a quick ratio of 0.96, a current ratio of 1.31 and a debt-to-equity ratio of 2.90. Solventum Co. has a one year low of $47.16 and a one year high of $96.05.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.